vs
Genasys Inc.（GNSS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Genasys Inc.的1.8倍（$30.3M vs $17.1M），Genasys Inc.净利率更高（-4.8% vs -221.3%，领先216.6%），Genasys Inc.同比增速更快（145.9% vs 43.0%），过去两年Genasys Inc.的营收复合增速更高（72.4% vs 39.4%）
杰纳斯公司总部位于美国加利福尼亚州圣地亚哥，核心业务涵盖声学设备与应急通讯 SaaS 服务。其主打产品远距离声学装置（LRAD）可实现远程定向发声与大规模灾害预警通知，另有Genasys Protect分区多渠道通讯系统、Evertel安全协作通讯工具，以及集成式远距离语音广播声学扬声器。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
GNSS vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.8倍
$17.1M
营收增速更快
GNSS
高出102.9%
43.0%
净利率更高
GNSS
高出216.6%
-221.3%
两年增速更快
GNSS
近两年复合增速
39.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $17.1M | $30.3M |
| 净利润 | $-817.0K | $-67.1M |
| 毛利率 | 48.0% | — |
| 营业利润率 | -2.1% | -190.0% |
| 净利率 | -4.8% | -221.3% |
| 营收同比 | 145.9% | 43.0% |
| 净利润同比 | 80.0% | -31.2% |
| 每股收益（稀释后） | $-0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GNSSRGNX
| Q4 25 | $17.1M | $30.3M | ||
| Q3 25 | $17.0M | $29.7M | ||
| Q2 25 | $9.9M | $21.4M | ||
| Q1 25 | $6.9M | $89.0M | ||
| Q4 24 | $6.9M | $21.2M | ||
| Q3 24 | $6.7M | $24.2M | ||
| Q2 24 | $7.2M | $22.3M | ||
| Q1 24 | $5.7M | $15.6M |
净利润GNSSRGNX
| Q4 25 | $-817.0K | $-67.1M | ||
| Q3 25 | $-1.4M | $-61.9M | ||
| Q2 25 | $-6.5M | $-70.9M | ||
| Q1 25 | $-6.1M | $6.1M | ||
| Q4 24 | $-4.1M | $-51.2M | ||
| Q3 24 | $-11.4M | $-59.6M | ||
| Q2 24 | $-6.7M | $-53.0M | ||
| Q1 24 | $-6.9M | $-63.3M |
毛利率GNSSRGNX
| Q4 25 | 48.0% | — | ||
| Q3 25 | 50.3% | — | ||
| Q2 25 | 26.3% | — | ||
| Q1 25 | 37.7% | — | ||
| Q4 24 | 45.8% | 70.2% | ||
| Q3 24 | 40.8% | 48.8% | ||
| Q2 24 | 52.8% | 52.5% | ||
| Q1 24 | 37.9% | 72.6% |
营业利润率GNSSRGNX
| Q4 25 | -2.1% | -190.0% | ||
| Q3 25 | 7.7% | -176.3% | ||
| Q2 25 | -60.1% | -296.3% | ||
| Q1 25 | -90.2% | 13.6% | ||
| Q4 24 | -85.6% | -242.1% | ||
| Q3 24 | -105.8% | -256.6% | ||
| Q2 24 | -74.8% | -251.3% | ||
| Q1 24 | -121.9% | -408.8% |
净利率GNSSRGNX
| Q4 25 | -4.8% | -221.3% | ||
| Q3 25 | -8.3% | -208.3% | ||
| Q2 25 | -65.8% | -331.8% | ||
| Q1 25 | -88.6% | 6.8% | ||
| Q4 24 | -58.8% | -241.3% | ||
| Q3 24 | -168.9% | -246.3% | ||
| Q2 24 | -93.2% | -237.7% | ||
| Q1 24 | -120.9% | -405.4% |
每股收益（稀释后）GNSSRGNX
| Q4 25 | $-0.02 | $-1.30 | ||
| Q3 25 | $-0.03 | $-1.20 | ||
| Q2 25 | $-0.14 | $-1.38 | ||
| Q1 25 | $-0.14 | $0.12 | ||
| Q4 24 | $-0.09 | $-0.99 | ||
| Q3 24 | $-0.26 | $-1.17 | ||
| Q2 24 | $-0.15 | $-1.05 | ||
| Q1 24 | $-0.16 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.3M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8M | $102.7M |
| 总资产 | $67.6M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GNSSRGNX
| Q4 25 | $10.3M | $230.1M | ||
| Q3 25 | $8.0M | $274.2M | ||
| Q2 25 | $5.5M | $323.3M | ||
| Q1 25 | $7.1M | $267.9M | ||
| Q4 24 | $13.6M | $234.7M | ||
| Q3 24 | $12.9M | $255.5M | ||
| Q2 24 | $12.7M | $290.4M | ||
| Q1 24 | $6.6M | $338.7M |
股东权益GNSSRGNX
| Q4 25 | $1.8M | $102.7M | ||
| Q3 25 | $2.2M | $161.5M | ||
| Q2 25 | $3.2M | $213.7M | ||
| Q1 25 | $8.1M | $274.2M | ||
| Q4 24 | $13.7M | $259.7M | ||
| Q3 24 | $17.6M | $301.4M | ||
| Q2 24 | $28.5M | $348.3M | ||
| Q1 24 | $34.9M | $390.7M |
总资产GNSSRGNX
| Q4 25 | $67.6M | $453.0M | ||
| Q3 25 | $63.9M | $525.2M | ||
| Q2 25 | $57.4M | $581.0M | ||
| Q1 25 | $49.7M | $490.9M | ||
| Q4 24 | $54.6M | $466.0M | ||
| Q3 24 | $53.9M | $519.1M | ||
| Q2 24 | $59.4M | $569.4M | ||
| Q1 24 | $51.0M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.2M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流GNSSRGNX
| Q4 25 | $7.2M | $-52.3M | ||
| Q3 25 | $2.5M | $-56.0M | ||
| Q2 25 | $-5.9M | $-49.3M | ||
| Q1 25 | $-6.3M | $33.6M | ||
| Q4 24 | $947.0K | $-31.6M | ||
| Q3 24 | $556.0K | $-40.5M | ||
| Q2 24 | $-7.5M | $-45.5M | ||
| Q1 24 | $-6.8M | $-55.5M |
自由现金流GNSSRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | $2.5M | $-56.5M | ||
| Q2 25 | $-5.9M | $-49.7M | ||
| Q1 25 | $-6.5M | $32.6M | ||
| Q4 24 | $878.0K | $-32.7M | ||
| Q3 24 | $526.0K | $-40.9M | ||
| Q2 24 | $-7.5M | $-46.0M | ||
| Q1 24 | $-6.8M | $-56.0M |
自由现金流率GNSSRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | 14.5% | -189.9% | ||
| Q2 25 | -59.9% | -232.8% | ||
| Q1 25 | -93.4% | 36.6% | ||
| Q4 24 | 12.7% | -154.2% | ||
| Q3 24 | 7.8% | -168.9% | ||
| Q2 24 | -105.0% | -206.2% | ||
| Q1 24 | -118.1% | -358.5% |
资本支出强度GNSSRGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.2% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 2.2% | 1.2% | ||
| Q4 24 | 1.0% | 5.1% | ||
| Q3 24 | 0.4% | 1.3% | ||
| Q2 24 | 0.1% | 2.1% | ||
| Q1 24 | 0.2% | 3.6% |
现金转化率GNSSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GNSS
| Hardware | $14.8M | 87% |
| Software | $2.3M | 13% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
